insider buying

insider buying Articles

Has Shift4 Payments CEO Jared Isaacman been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has Napco Security Technologies CEO Richard Soloway been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has CrowdStrike CEO George Kurtz been increasing or decreasing his share count over the past year? Does he know something we don’t?
Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to action.
Has Broadcom CEO Tan Hock been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has NewMarket CEO Thomas Gottwald been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has Procore Technologies CEO Craig Courtemanche been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has ZoomInfo Technologies CEO Henry Schuck been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has BlackRock CEO Larry Fink been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has Freshworks CEO Girish Mathrubootham been increasing or decreasing his share count over the past year? Does he know something we don’t?
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Has NerdWallet CEO Tim Chen been increasing or decreasing his share count over the past year? Does he know something we don’t?
Has Trade Desk CEO Jeffrey Green been increasing or decreasing his shares over the past year? Does he know something we don’t?
Has Prospect Capital CEO John Barry been increasing or decreasing his share count over the past year? Does he know something we don’t?
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.